Equity Overview
Price & Market Data
Price: $5.07
Daily Change: -$0.15 / 2.96%
Range: $5.00 - $5.60
Market Cap: $82,559,376
Volume: 115,636
Performance Metrics
1 Week: 4.32%
1 Month: -38.99%
3 Months: -29.58%
6 Months: 2.63%
1 Year: -47.95%
YTD: -0.59%
Company Details
Employees: 32
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.